COMP <GO>
NUVB vs ANIP // DIVIDEND YIELD & FCF PAYOUT SAFETY
Nuvation Bio Inc. (Class A) (NYSE) VS. ANI Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: NUVB 1
— ANIP 9
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: ANIP
LAST: $4.77 (+3.92%) • MKT CAP: $1.67B
dividend-safety
0.00%
LAST: $73.16 (+2.02%) • MKT CAP: $1.68B
dividend-safety
0.07%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUVB VS. ANIP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUVB | ANIP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 16.00% | -51.00 | ANIP | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 13.7x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -10.35% | 10.20% | -20.55 | ANIP | /fcf-yield <GO> |
| Operating Margin | -60.00% | 12.60% | -72.60 | ANIP | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 8.80% | -68.80 | ANIP | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 43.80% | +136.20 | NUVB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.07% | -0.07 | ANIP | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.76 | 2.36 | -1.60 | ANIP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | ANIP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.2 | 47.2 | -4.93 | ANIP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.67B | $1.68B | -$4.9M | ANIP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUVB REV | ANIP REV | NUVB GROSS % | ANIP GROSS % | NUVB FCF | ANIP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.9M | $883.4M | — | — | -$173.4M | $171.4M |
| FY 2024 | $7.9M | $614.4M | 10.1% | — | -$130.4M | $47.8M |
| FY 2023 | $0 | $486.8M | — | — | -$68.0M | $119.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUVB // BETA —
ANIP // BETA —